Article Text

PDF

Effects of captopril (SQ 14,225) in a patient with primary pulmonary hypertension.
  1. J. D. Horowitz,
  2. J. B. Brennan,
  3. L. E. Oliver,
  4. D. Harding,
  5. A. J. Goble,
  6. W. J. Louis

    Abstract

    In a 33-year-old patient with severe primary pulmonary hypertension, the acute administration of the angiotensin-converting-enzyme inhibitor captopril (SQ 14,225) induced a rise in cardiac output, and a fall in both pulmonary and systemic vascular resistance. Subsequent chronic oral administration of captopril induced only transient clinical improvement, and the patient died. Captopril may nevertheless be useful in the treatment of less advanced cases of this disease.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.